The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications.

IF 9.5 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Biomarker Research Pub Date : 2024-12-19 DOI:10.1186/s40364-024-00705-7

Alan Hodges, Rachel Dubuque, Shu-Hsia Chen, Ping-Ying Pan

{"title":"The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications.","authors":"Alan Hodges, Rachel Dubuque, Shu-Hsia Chen, Ping-Ying Pan","doi":"10.1186/s40364-024-00705-7","DOIUrl":null,"url":null,"abstract":"<p><p>The leukocyte immunoglobulin-like receptor B (LILRB) proteins, characterized by their transmembrane nature and canonical immunoreceptor tyrosine-based inhibitory motifs (ITIM) signaling, play a pivotal role in maintaining immune homeostasis and are implicated in the pathogenesis of various disease states. This comprehensive review will focus on the intricate involvement of the LILRB family in hematologic malignancies. These receptors have emerged as valuable diagnostic and prognostic biomarkers in leukemia, lymphoma, and myeloma. Beyond their prognostic implications, LILRBs actively shape the immune microenvironment and directly influence the disease pathogenesis of hematologic malignancies. Furthermore, their identification as potential therapeutic targets offer a promising avenue for precision medicine strategies in the treatment of these disorders. Currently, multiple LILRB directed therapies are in the preclinical and clinical trial pipelines. This review underscores the multifaceted role of the LILRB family in hematologic malignancies, highlighting their significance from diagnostic and prognostic perspectives to their broader impact on disease pathophysiology and as valuable therapeutic targets.</p>","PeriodicalId":54225,"journal":{"name":"Biomarker Research","volume":"12 1","pages":"159"},"PeriodicalIF":9.5000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658067/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarker Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40364-024-00705-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

The leukocyte immunoglobulin-like receptor B (LILRB) proteins, characterized by their transmembrane nature and canonical immunoreceptor tyrosine-based inhibitory motifs (ITIM) signaling, play a pivotal role in maintaining immune homeostasis and are implicated in the pathogenesis of various disease states. This comprehensive review will focus on the intricate involvement of the LILRB family in hematologic malignancies. These receptors have emerged as valuable diagnostic and prognostic biomarkers in leukemia, lymphoma, and myeloma. Beyond their prognostic implications, LILRBs actively shape the immune microenvironment and directly influence the disease pathogenesis of hematologic malignancies. Furthermore, their identification as potential therapeutic targets offer a promising avenue for precision medicine strategies in the treatment of these disorders. Currently, multiple LILRB directed therapies are in the preclinical and clinical trial pipelines. This review underscores the multifaceted role of the LILRB family in hematologic malignancies, highlighting their significance from diagnostic and prognostic perspectives to their broader impact on disease pathophysiology and as valuable therapeutic targets.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血液恶性肿瘤中的LILRB家族：预后关联、机制考虑和治疗意义。

白细胞免疫球蛋白样受体B （LILRB）蛋白以其跨膜性质和典型免疫受体酪氨酸基抑制基序（ITIM）信号传导为特征，在维持免疫稳态中起关键作用，并与各种疾病状态的发病机制有关。这篇全面的综述将集中在LILRB家族在血液恶性肿瘤中的复杂参与。这些受体在白血病、淋巴瘤和骨髓瘤中已成为有价值的诊断和预后生物标志物。除了对预后的影响外，LILRBs还积极塑造免疫微环境，并直接影响血液恶性肿瘤的发病机制。此外，它们作为潜在治疗靶点的鉴定为治疗这些疾病的精准医学策略提供了一条有希望的途径。目前，多种LILRB定向疗法正处于临床前和临床试验阶段。本综述强调了LILRB家族在血液系统恶性肿瘤中的多方面作用，从诊断和预后的角度强调了它们对疾病病理生理学的广泛影响以及作为有价值的治疗靶点的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomarker Research Biochemistry, Genetics and Molecular Biology-Molecular Medicine

CiteScore

15.80

自引率

1.80%

发文量

审稿时长

10 weeks

期刊介绍： Biomarker Research, an open-access, peer-reviewed journal, covers all aspects of biomarker investigation. It seeks to publish original discoveries, novel concepts, commentaries, and reviews across various biomedical disciplines. The field of biomarker research has progressed significantly with the rise of personalized medicine and individual health. Biomarkers play a crucial role in drug discovery and development, as well as in disease diagnosis, treatment, prognosis, and prevention, particularly in the genome era.